1445993-26-9

Usage

Uses

Used in Oncology:
ABBV-075 is used as an anticancer agent for its potent anti-tumor activity in multiple cancer models. It targets the overactive Wnt pathway, which is implicated in many types of cancer, making it a promising candidate for further clinical development and potential treatment of cancer.
Used in Combination Therapy:
ABBV-075 is used as a combination therapy agent for its synergistic effects when combined with other anticancer agents. This enhances the chemo-sensitivity and efficacy of the treatment, particularly in resistant cases.
Used in Drug Development:
ABBV-075 is used as a candidate for further clinical development due to its promising results in preclinical studies and its potential to target the Wnt pathway, which is overactive in many types of cancer. Its development could lead to new treatment options for cancer patients.

Upstream product

• 1445993-89-4 6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1446235-98-8 4-[5-amino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-1-tosyl-1,6-dihydro-7H-pyrrolo[2,3-c] pyridin-7-one 
• 1445994-28-4 4-(5-amino-2-(2,4-difluorophenoxy)phenyl)-6-methyl-1H-pyrrolo[2,3-c]pyridine-7(6H)-one 
• 594-44-5 Ethanesulfonyl chloride 
• 1445993-88-3 4-(2-fluoro-5-nitrophenyl)-6-methyl-1-tosyl-1H-pyrrolo[2,3-c]-pyridin-7(6H)-one 
• 701-45-1 2-bromo-1-fluoro-4-nitrobenzene 
• 884495-14-1 5-bromo-2-methoxy-4-methyl-3-nitropyridine 
• 1445993-87-2 4-bromo-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1445993-86-1 4-bromo-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1445993-85-0 4-bromo-7-methoxy-1-(4-methylbenzenesulfonyl)pyrrolo[2,3-c]pyridine 
• 367-27-1 2,4-difluorophenol 
• 425380-37-6 4-bromo-7-methoxy-1-hydro-pyrrolo[2,3-c]pyridine 

Downstream Products

• 1446235-81-9 N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-N-(2-methoxyethyl)ethanesulfonamide 
• 1446235-29-5 N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-N-[2-(dimethylamino)ethyl]ethanesulfonamide 

Relevant academic research and scientific papers

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest. An effort to generate novel BET bromodomain inhibi

CRYSTALLINE BROMODOMAIN INHIBITORS

N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3- c]pyridin-4-yl)phenyl]ethanesulfonamide and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.

BROMODOMAIN INHIBITORS

Provided are compounds of formula (I), wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).